Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. has a market price of $56.29 and a market cap of $2.76 billion, with a price-to-earnings ratio of 20.25 and a price-to-book ratio of 2.54. The company's liquidity position is characterized by a current ratio of 3.11, indicating a strong ability to meet short-term obligations, although its cash and equivalents of $62.37 million are significantly lower than its long-term debt of $1.13 billion. The company's return on equity of 7.45% and return on assets of 3.9% suggest moderate profitability relative to its equity and asset base. The company's operating income of $233.92 million and net income of $136.37 million reflect a gross profit margin of 55.67% and an operating margin of 29.0%, which are key indicators of its profitability. These figures are compared against the industry's preferred metrics, which typically emphasize gross margin and operating margin as primary indicators of financial health. The company's debt-to-equity ratio of 0.62 indicates a moderate level of leverage, which is generally considered acceptable in the pharmaceuticals industry. Prestige Consumer Healthcare Inc. operates in two main segments: North American OTC Healthcare and International OTC Healthcare. The company's revenue is primarily concentrated in North America, with a significant portion derived from a limited number of customers, which poses a concentration risk. The company's international operations are less developed, and the company faces challenges in expanding its international sales due to export or import restrictions and tariffs. The company's growth trajectory is influenced by its ability to develop and execute effective sales, advertising, and marketing programs to maintain or grow its market share. The company's outlook for the current fiscal year indicates a focus on capital allocation and the potential for new product introductions. The company's capital expenditure of $5.97 million in the most recent quarter suggests a moderate investment in infrastructure and production capabilities. The company's risk assessment highlights medium liquidity and dilution risks. The company's net cash is negative after subtracting total debt, and source documents mention dilution or offering risk. The company is exposed to various risks, including supply chain disruptions, regulatory actions, and geopolitical events, which could impact its operations and financial performance. The company's insider trading score of 4.0 indicates a relatively low level of insider trading activity, which is a positive signal for investors. Recent events and filings indicate that the company is navigating a volatile economic environment, with potential impacts on prices, supply, and demand for its products. The company has experienced shortages of certain products, particularly eye care products, due to difficulties in meeting demand by third-party manufacturers. The company's forward-looking statements are subject to various risks and uncertainties, including disruptions in the supply of sourced goods, price increases for raw materials, and regulatory actions.